InvestSMART

Botanix Pharmaceuticals Ltd (ASX: BOT) - Announcements

Current share price for BOT : $0.009 0.001 (10%)+

ASX company news and announcements for Botanix Pharmaceuticals Ltd (BOT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Botanix Pharmaceuticals Ltd (BOT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Botanix Pharmaceuticals Ltd (BOT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Botanix Pharmaceuticals Ltd (BOT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$25 Apendix 4G 27 Aug 2021 9:18AM $0.075 $0.009 fallen by 88%
$25 Annual General Meeting 27 Aug 2021 9:13AM $0.075 $0.009 fallen by 88%
$25 Appendix 4C - Quarterly 23 Jul 2021 8:25AM $0.081 $0.009 fallen by 88.89%
$25 New Canine Pilot Study Supports Further AD Investigation 17 May 2021 8:55AM $0.078 $0.009 fallen by 88.46%
$25 Updated Investor Presentation and Conference Call 5 May 2021 9:29AM $0.084 $0.009 fallen by 89.29%
$25 Botanix Update on BTX 1801 Clinical Development 4 May 2021 9:01AM $0.082 $0.009 fallen by 89.02%
$25 Appendix 4C - Quarterly 30 Apr 2021 9:34AM $0.084 $0.009 fallen by 89.29%
$25 Publication and Awareness boosts BOT Antimicrobial Platform 27 Apr 2021 8:31AM $0.086 $0.009 fallen by 89.53%
$25 BTX 1702 Rosacea Study Approval 30 Mar 2021 9:19AM $0.100 $0.009 fallen by 91%
$25 Botanix Presenting at ASX Small and Mid-Cap Conference 16 Mar 2021 9:39AM $0.105 $0.009 fallen by 91.43%
$25 Final Director's Interest Notice 3 Mar 2021 9:42AM $0.110 $0.009 fallen by 91.82%
$25 Botanix Expands Management Team 1 Mar 2021 9:25AM $0.110 $0.009 fallen by 91.82%
$25 Half Yearly Report and Accounts 26 Feb 2021 6:09PM $0.110 $0.009 fallen by 91.82%
$25 Presentation - Dermatology Drug Development Summit Europe 19 Feb 2021 9:46AM $0.135 $0.009 fallen by 93.33%
$25 Botanix receives A$6.87m R&D Tax Incentive Refund 12 Feb 2021 8:20AM $0.145 $0.009 fallen by 93.79%
$25 Phase 2a Study Shows BTX 1801 Eradicates S. Aureus 3 Feb 2021 9:24AM $0.145 $0.009 fallen by 93.79%
$25 Trading Halt 1 Feb 2021 9:49AM $0.145 $0.009 fallen by 93.79%
$25 Appendix 4C - Quarterly 22 Jan 2021 11:11AM $0.175 $0.009 fallen by 94.86%
$25 Antimicrobial Data Published in Peer-Reviewed Journal 20 Jan 2021 8:24AM $0.135 $0.009 fallen by 93.33%
$25 Appendix 2A and Notice Under Section 708A 17 Dec 2020 5:14PM $0.120 $0.009 fallen by 92.50%
$25 Update on BTX 1801 Phase 2a Clinical Study 14 Dec 2020 9:25AM $0.125 $0.009 fallen by 92.80%
$25 Results of Meeting 23 Nov 2020 2:36PM $0.125 $0.009 fallen by 92.80%
$25 AGM Presentation 23 Nov 2020 11:38AM $0.135 $0.009 fallen by 93.33%
$25 FDA Clears Development Path for BTX 1801 11 Nov 2020 9:31AM $0.095 $0.009 fallen by 90.53%
$25 Letter to Shareholders - AGM 21 Oct 2020 6:34PM $0.094 $0.009 fallen by 90.43%

426 - 450 of 726 results

Page 18 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.